The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Author(s):  
Christine Garcia ◽  
Kari L. Ring
2000 ◽  
Vol 75 (1) ◽  
pp. 60-71 ◽  
Author(s):  
Resad Pasic ◽  
Robert D. Hilgers ◽  
Ronald L. Levine

Cancer ◽  
1983 ◽  
Vol 51 (S12) ◽  
pp. 2480-2484 ◽  
Author(s):  
J. Taylor Wharton ◽  
Creighton L. Edwards

Brachytherapy ◽  
2017 ◽  
Vol 16 (3) ◽  
pp. S62-S63
Author(s):  
Silvia Rodriguez Villalba ◽  
Antonio Otal Palacin ◽  
Jose Richart Sancho ◽  
Rosa Cañon Rodriguez ◽  
Jose Perez-Calatayud ◽  
...  

2019 ◽  
Vol 70 (1) ◽  
pp. e377 ◽  
Author(s):  
Bettina Langhans ◽  
Hans Dieter Nischalke ◽  
Benjamin Kraemer ◽  
Leona Dold ◽  
Philipp Lutz ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
Julie Jacobs ◽  
Evelien Smits ◽  
Filip Lardon ◽  
Patrick Pauwels ◽  
Vanessa Deschoolmeester

Colorectal cancer (CRC), as one of the most prevalent types of cancer worldwide, is still a leading cause of cancer related mortality. There is an urgent need for more efficient therapies in metastatic disease. Immunotherapy, a rapidly expanding field of oncology, is designed to boost the body’s natural defenses to fight cancer. Of the many approaches currently under study to improve antitumor immune responses, immune checkpoint inhibition has thus far been proven to be the most effective. This review will outline the treatments that take advantage of our growing understanding of the role of the immune system in cancer, with a particular emphasis on immune checkpoint molecules, involved in CRC pathogenesis.


2021 ◽  
Vol 72 (6) ◽  
Author(s):  
Francesco Plotti ◽  
Roberto Angioli

Sign in / Sign up

Export Citation Format

Share Document